(PharmaNewsWire.Com, May 25, 2021 ) The global animal parasiticides market is projected to reach USD 13.7 billion by 2025 from USD 9.7 billion in 2020, at a CAGR of 7.2% during the forecast period. The increased pet population and increasing rising prevalence of zoonotic diseases are driving the growth of the animal parasiticides market. The base year considered for the study is 2019, while the forecast period is 2020 to 2025.
The global animal parasiticides market is fragmented, with many regional and global players vying for larger market shares. Bayer AG (Germany), Boehringer Ingelheim (Germany), Elanco (US), Zoetis (US), Merck (US), and PetIQ (US) are the major players in this market.
Boehringer Ingelheim was a leading player in the animal parasiticides market in 2019. The company’s strong focus on R&D and investments in collaborations, partnerships, and acquisitions have ensured its position in the market. It focuses on expansions to strengthen its geographic footprint, presence, and growth. For instance, in August 2019, the company opened a Health Management Center in China.
Bayer has a strong portfolio of parasiticides for companion as well as livestock animals. Over the years, the company has maintained its leading position in the market through continuous innovation and the launch of advanced products. In this regard, in 2019, it launched three products in China. In addition, Bayer focuses on expanding its product portfolio and geographic presence by means of agreements, partnerships, and joint ventures. For example, in July 2018, Bayer Animal Health GmbH signed a global license agreement with Mitsui Chemicals Agro (Japan) to develop innovative parasiticides for companion animals based on MCAG’s innovation and technology.
Elanco (US) is one of the largest players in the animal parasiticides market. In order to remain competitive and grow, the company focuses on expanding and deepening its partnerships with existing customers, enhancing operation excellence and quality, enhancing capabilities and expertise, and developing innovative products. The company pursues a number of organic and inorganic growth strategies.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
